Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Applied Database Study of Oculomotor-Pupillary Biomarkers Using Edge AI for Clinical Evaluation and Prediction in Parkinson's Disease

NCT07886450 is registered in ClinicalTrials.gov with The Hong Kong Polytechnic University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07886450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Applied Database Study of Oculomotor-Pupillary Biomarkers Using Edge AI for Clinical Evaluation and Prediction in Parkinson's Disease
Lead sponsor
The Hong Kong Polytechnic University
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2027
Enrollment
128 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease (disorder)

Arms

As registered; 2 arms.

  • Parkinson's Disease Group Edge-AI Eye-Tracking Assessment
  • Healthy Control Group Edge-AI Eye-Tracking Assessment

Primary endpoints

Registered primary outcome measures; 3 primary.

  • Differences in mean prosaccade gain between early-to-moderate PD patients and healthy controls. Baseline

    Prosaccade gain is defined as the ratio of the primary saccade amplitude to the target displacement amplitude, measured using a head-mounted infrared eye-tracking device. The mean gain across valid trials will be calculated for each participant. Mean prosaccade gain will be compared between patients with early-to-moderate PD and healthy controls.

  • Differences in antisaccade directional error rate between early-to-moderate PD patients and healthy controls. Baseline

    Antisaccade directional error rate is defined as the percentage of valid antisaccade trials in which the initial saccade is incorrectly directed toward the visual target rather than in the opposite direction, measured using a head-mounted infrared eye-tracking device. The error rate will be calculated for each participant as the number of directional error trials divided by the total number of valid antisaccade trials, multiplied by 100. Antisaccade directional error rate will be compared between patients with early-to-moderate PD and healthy controls.

  • Differences in mean prosaccade peak velocity between early-to-moderate PD patients and healthy controls. Baseline

    Prosaccade peak velocity is defined as the maximum angular eye velocity during the primary prosaccade, measured in degrees per second (°/s) using a head-mounted infrared eye-tracking device. The mean peak velocity across valid trials will be calculated for each participant. Mean prosaccade peak velocity will be compared between patients with early-to-moderate PD and healthy controls.

Lead sponsor's other trials

The Hong Kong Polytechnic University, most recent start first.

Similar trials

Same condition (Parkinson Disease) and phase, most recent start first.